Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

NCT03897036 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Basal Cell

Interventions

DRUG: CX-4945

Sponsor

Senhwa Biosciences, Inc.